Gusso M I, Guzzo G C, Pennisi M
Minerva Med. 1985 Mar 24;76(12):567-73.
Ninety-seven patients (44 males and 53 females of mean age 42.6 +/- 12,9 years) with orthopedic-traumatologic disorders (osteoarthritis, 38; painful joints, 26; fibrositis, painful shoulder, 20; peri- and extra-articular disorders, 13) had been treated during 7 to 30 days with two suppositories (400 mg) or three capsules (450 mg) proglumetacin (Proxil Rorer). Most patients responded well to very well to the treatment with significant improvement of pain and inflammatory symptoms as well as restoring of limited function. Such a response resulted proportional to the dose (53% of good responders among those given the lower dose and 82% among those at the higher dose) and to the kind of pathology. The patients with acute disorders (7) responded all very well in 7 days; those with subacute disorders (57) responded well to very well in a proportion of 57% within 15 days; those with chronic disorders responded to a proportion of 48% within 30 days. Tolerance resulted very good anyway: in no case had the treatment to be withdrawn, nor allergic or C.S.N. reactions were observed, so that the overall tolerance was defined excellent to good in 90% of patients. Thirty-three patients complained of accessory symptoms, mainly epigastric pain and nausea, almost always mild and anyway transient. Proglumetacin can therefore be properly defined as a firstchoice treatment for the management, also ambulatory, of orthopedic-traumatologic disorders.
97例骨科创伤性疾病患者(44例男性,53例女性,平均年龄42.6±12.9岁),包括骨关节炎38例、疼痛性关节病26例、纤维织炎及肩部疼痛20例、关节周围和关节外疾病13例,接受了7至30天的治疗,使用两粒栓剂(400毫克)或三粒胶囊(450毫克)的丙谷美辛(Proxil Rorer)。大多数患者对治疗反应良好至极好,疼痛和炎症症状显著改善,功能受限得到恢复。这种反应与剂量(低剂量组中53%反应良好,高剂量组中82%反应良好)及病理类型成正比。急性疾病患者(7例)在7天内均反应良好;亚急性疾病患者(57例)中57%在15天内反应良好至极好;慢性疾病患者在30天内48%有反应。无论如何耐受性都非常好:无一例需要停止治疗,未观察到过敏或中枢神经系统反应,因此90%的患者总体耐受性被定义为优秀至良好。33例患者抱怨有附加症状,主要是上腹部疼痛和恶心,几乎总是轻微且短暂的。因此,丙谷美辛可被恰当地定义为骨科创伤性疾病门诊治疗的首选药物。